Role of folate-binding protein in ovarian cancer treatment
Author Information
Author(s): S Sen, E Erbal, M D'Incalci, F Bottero, S Canevari, A Tomassetti
Primary Institution: Mario Negri Institute
Hypothesis
The study investigates the cytotoxicity potential of DDATHF as a function of folate-binding protein (FBP) expression.
Conclusion
FBP expression is an important factor for the cytotoxicity of DDATHF, but it is not a reliable predictor of sensitivity to the drug in ovarian cancer cells.
Supporting Evidence
- FBP expression increased in some ovarian cancer cell lines when grown in low folate conditions.
- DDATHF showed increased cytotoxicity in ovarian cancer cells when folic acid was depleted from the medium.
- FBP-tNIH/3T3 cells were significantly more sensitive to DDATHF compared to mock-tNIH/3T3 cells.
Takeaway
This study looks at how a protein that binds folate affects the ability of a cancer drug to kill ovarian cancer cells. It finds that while this protein helps the drug work better, it's not the only thing that matters.
Methodology
The cytotoxicity of DDATHF was evaluated in ovarian carcinoma cell lines using a standard clonogenic assay, with cells grown in media containing different folate concentrations.
Limitations
FBP expression alone cannot predict the sensitivity of ovarian cancer cells to DDATHF.
Want to read the original?
Access the complete publication on the publisher's website